TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24463223

Group type: EXPERIMENTAL
Intervention: Pressure sensor/metronome device (CPREzy)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Accelerometer device (Phillips Q‐CPR)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Simple metronome
Number of subjects: 3
Study: 24637998

Group type: EXPERIMENTAL
Intervention: Involved-node radiotherapy (IN-RT) omitted after negative early PET scan following two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Standard combined-modality treatment (including IN-RT)
Number of subjects: 1137
Study: 21806490

Group type: EXPERIMENTAL
Intervention: Foley catheter with extra‐amniotic saline infusion
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cook cervical ripening balloon
Number of subjects: 188
Study: 19089532

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg TID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17200777

Group type: EXPERIMENTAL
Intervention: Nadroparin 5750 anti‐Xa IU s.c. twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiplatelet treatment
Number of subjects: 60
Study: 15831779

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 77
Study: 11937423

Group type: EXPERIMENTAL
Intervention: Antibiotic monotherapy
Number of subjects: 4795

Group type: COMPARATOR
Intervention: Aminoglycoside-containing combination therapy
Number of subjects: 4795
Study: 9701716

Group type: EXPERIMENTAL
Intervention: ipsapirone (0.3 mg/kg, orally)
Number of subjects: 34
Study: 8532263

Group type: EXPERIMENTAL
Intervention: Routine peritoneal closure
Number of subjects: 106

Group type: COMPARATOR
Intervention: No peritoneal closure
Number of subjects: 106
Study: 1984877

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 units/2‐5 min)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Streptokinase (1.5 million units/60 min)
Number of subjects: 370
Study: 6841923

Group type: EXPERIMENTAL
Intervention: Active treatment (chlorthalidone 15 mg and clonidine 0.1 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30820660

Group type: EXPERIMENTAL
Intervention: Heat stimulation (temperature increase from 20 to 40 °C at 2 °C/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cold stimulation (temperature decrease from 40 to 20 °C at 2 °C/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heat stimulation (temperature increase)
Number of subjects: 14
Study: 29491276

Group type: EXPERIMENTAL
Intervention: Passion fruit seed extract (5 mg piceatannol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 32
Study: 27074935

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 24962549

Group type: EXPERIMENTAL
Intervention: Topical recombinant human EGF (rhEGF) cream applied twice daily for six weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream (control) applied twice daily for six weeks
Number of subjects: 20
Study: 22424564

Group type: EXPERIMENTAL
Intervention: DBS (subthalamic nucleus or globus pallidus internus)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DBS+DOPA (both medication and DBS on)
Number of subjects: 24

Group type: COMPARATOR
Intervention: OFF/OFF (off medication with DBS switched off)
Number of subjects: 24

Group type: COMPARATOR
Intervention: DOPA (on medication with DBS off)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GPi group
Number of subjects: 24

Group type: COMPARATOR
Intervention: PD control group
Number of subjects: 24
Study: 19175369

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BIAsp70
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BIAsp30
Number of subjects: 19
Study: 17460427

Group type: EXPERIMENTAL
Intervention: Early intravitreal triamcinolone injection (4 mg/0.1 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Late intravitreal triamcinolone injection (4 mg/0.1 ml)
Number of subjects: 20
Study: 15234072

Group type: EXPERIMENTAL
Intervention: DAG oil (0.5 g/kg body weight/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: TAG oil (0.5 g/kg body weight/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 81

Group type: COMPARATOR
Intervention: TAG oil
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DAG oil and TAG oil
Number of subjects: 81
Study: 12399675

Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metronidazole 0.75% gel
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 63
Study: 9661552

Group type: EXPERIMENTAL
Intervention: i.v. patient-controlled analgesia (PCA) with morphine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: continuous 3-in-1 block
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: epidural analgesia
Number of subjects: 45
Study: 8187514

Group type: EXPERIMENTAL
Intervention: Physiologic concentrations of faecal enzymes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phosphate buffer (pH = 8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme mixture containing lipase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged occlusive exposure to digestive enzymes
Number of subjects: 0
Study: 1792811

Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 mg bid or 5 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 6576203

Group type: EXPERIMENTAL
Intervention: Intermediate dose methotrexate (ID-MTX) pulses
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional vincristine (VCR) pulses
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: COALL-80 induction therapy modification
Number of subjects: 145
Study: 30811354

Group type: EXPERIMENTAL
Intervention: Tissue adhesive as an adjunct to standard three-layer closure
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard three-layer closure with staples (Control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tissue adhesive and standard closure
Number of subjects: 29
Study: 29772277

Group type: EXPERIMENTAL
Intervention: 0.1%‐fluorometholone (FML), 4 drops daily for 22 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Polyvinyl‐alcohol (PA), 4 drops daily for 22 days
Number of subjects: 41
Study: 26874371

Group type: EXPERIMENTAL
Intervention: ReNu Multiplus(®) in study CLCs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SoloCare Aqua™ in study CLCs
Number of subjects: 20

Group type: COMPARATOR
Intervention: New lenses in new cases with fresh solution (control CLCs)
Number of subjects: 20
Study: 24313663

Group type: EXPERIMENTAL
Intervention: Brief functional relaxation (FR) training via MP3 player
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care (15 minutes of sitting quietly)
Number of subjects: 48
Study: 21635200

Group type: EXPERIMENTAL
Intervention: Early epidural analgesia (EEA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional epidural analgesia (CEA)
Number of subjects: 41
Study: 19279518

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Colestimide (3.0 g/day)
Number of subjects: 40
Study: 17704416

Group type: EXPERIMENTAL
Intervention: Lapuleucel-T (APC8024) infusion at weeks 0, 2, and 4; no specific dosage mentioned.
Number of subjects: 19
Study: 15058177

Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Compomer/composite open sandwich restorations
Number of subjects: 133

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 133
Study: 12238277

Group type: EXPERIMENTAL
Intervention: Double antibiotherapy for 10 to 14 days with a double dose of an anti-secretory drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current regimen (7 days of double-dose anti-secretory drug and 2 antibiotics, followed by usual dose for 3 weeks)
Number of subjects: 0
Study: 9525444

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fexofenadine 240 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fexofenadine 240 mg single dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clemastine 2 mg twice daily
Number of subjects: 24
Study: 7848623

Group type: EXPERIMENTAL
Intervention: Active drug therapy (one of five active drugs)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Nutritional‐hygienic therapy and active drugs
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 2595644

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous PK 11195
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 4590668

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol at a dosage of 400 to 800 mug/day for three months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate) at a daily maintenance dose of 200 mug/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Steroid aerosols (betamethasone valerate or beclomethasone dipropionate)
Number of subjects: 120
Study: 31491556

Group type: EXPERIMENTAL
Intervention: Bright light (BL) exposure (>8000 lx) during memory encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control light (CL) exposure (<500 lx) during memory encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bright light (BL) exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control light (CL) exposure
Number of subjects: 0
Study: 28513492

Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Orbscan
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sirius
Number of subjects: 46
Study: 25683592

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Prednisolone (0.5 mg kg(-1) daily)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 256

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 256
Study: 23533302

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) 1.2 g/day for 12 weeks
Number of subjects: 0
Study: 22134936

Group type: EXPERIMENTAL
Intervention: sedated endoscopy (sEGD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: unsedated transnasal endoscopy (uTNE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: video capsule endoscopy (VCE)
Number of subjects: 60
Study: 19620697

Group type: EXPERIMENTAL
Intervention: Eccentric compression applied by a crossed-tape technique (group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No eccentric compression (group B)
Number of subjects: 200
Study: 16798758

Group type: EXPERIMENTAL
Intervention: Ramp ATP therapy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Burst+ ATP therapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 176
Study: 12769158

Group type: EXPERIMENTAL
Intervention: HDk lotrafilcon A soft contact lens
Number of subjects: 134

Group type: COMPARATOR
Intervention: LDk etafilcon A soft contact lens
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both lenses
Number of subjects: 134
Study: 11261130

Group type: EXPERIMENTAL
Intervention: Specialist nurses providing information, advice and support to caregivers and patients at home during the first year after a stroke.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Qualitative methods using semi-structured interviews.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 45
Study: 9048271

Group type: EXPERIMENTAL
Intervention: Delayed-release oral azathioprine 200 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delayed-release oral azathioprine 400 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delayed-release oral azathioprine 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard oral azathioprine 100 mg (control)
Number of subjects: 30
Study: 8104966

Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg every 12 hours
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Azelastine 8 mg every 12 hours
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chlorpheniramine 12 mg every 12 hours
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Azelastine (both doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Azelastine and Chlorpheniramine
Number of subjects: 15
Study: 3535933

Group type: EXPERIMENTAL
Intervention: L-PAM plus 5-FU (PF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF plus tamoxifen (PFT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumors with ER or PR ≥ 10 fmol or good nuclear grade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuclear grade in combination with either or both of the receptors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing number of favorable tumor prognostic indicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 0
Study: 31629325

Group type: EXPERIMENTAL
Intervention: Modified Star Excursion Balance Test (mSEBT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Y-Balance Test (YBT)
Number of subjects: 86
Study: 30063470

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem-cell transplantation (HSCT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative regimens (various)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alemtuzumab as a conditioning agent
Number of subjects: 75
Study: 27334138

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFAs (722 mg DHA)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU) + n-3 LCPUFAs (722 mg DHA)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 168
Study: 24836309

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 22691894

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg for 6 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg for 3 days after 4 mg for 3 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 6 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alprazolam 1 mg on day 6
Number of subjects: 18
Study: 20082144

Group type: EXPERIMENTAL
Intervention: Surgery plus 5-FU/LV
Number of subjects: 2966

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 2966
Study: 18842795

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg as sulfate) and micronutrients 5 d/wk for 10 wk
Number of subjects: 54

Group type: COMPARATOR
Intervention: Micronutrients alone 5 d/wk for 10 wk
Number of subjects: 54
Study: 15655095

Group type: COMPARATOR
Intervention: Out-patient management by primary care physicians
Number of subjects: 2145

Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 2145
Study: 12192466

Group type: EXPERIMENTAL
Intervention: Intravenous citalopram
Number of subjects: 0
Study: 11145369

Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: TCu380S
Number of subjects: 1568
Study: 8540873

Group type: EXPERIMENTAL
Intervention: salbutamol 200 micrograms via Breath‐A‐Tech spacer
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: salbutamol 200 micrograms via Volumatic spacer
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: salbutamol 1 mg in 2 mL saline via jet nebuliser
Number of subjects: 27

Group type: COMPARATOR
Intervention: Breath‐A‐Tech spacer
Number of subjects: 27

Group type: COMPARATOR
Intervention: Volumatic spacer
Number of subjects: 27
Study: 1742775

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7148373

Group type: EXPERIMENTAL
Intervention: Incentive spirometry combined with chest physical therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chest physical therapy alone
Number of subjects: 20
Study: 31607623

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and strength training program (group A), 3 times per week for 12 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (group B)
Number of subjects: 40
Study: 28750640

Group type: EXPERIMENTAL
Intervention: TCH (docetaxel, carboplatin, trastuzumab)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TCL (docetaxel, carboplatin, lapatinib)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TCHL (docetaxel, carboplatin, trastuzumab, lapatinib)
Number of subjects: 74
Study: 25039260

Group type: EXPERIMENTAL
Intervention: Eight self-administered weekly treatments with an 810-nm home-use laser at 5.0-6.4 J cm(‐2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (zero treatments)
Number of subjects: 36
Study: 23432535

Group type: EXPERIMENTAL
Intervention: Diltiazem supplement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine doses of tacrolimus (Control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CYP3A5 polymorphism-guided dosing equation
Number of subjects: 120
Study: 21226883

Group type: EXPERIMENTAL
Intervention: Smoking reduction counselling plus free nicotine replacement therapy (NRT)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Simple cessation advice
Number of subjects: 1154
Study: 19964700

Group type: EXPERIMENTAL
Intervention: Mobile diabetes management systems (telemonitoring)
Number of subjects: 0
Study: 17626647

Group type: EXPERIMENTAL
Intervention: Boston Scientific Flexima 8.3F pigtail nephrostomy tube #27‐180 (PIG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Boston Scientific 8.2F nephroureteral stent #410‐126 (NUS)
Number of subjects: 18
Study: 15625361

Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (SRS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SPECT (part of SRS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Median metastasis size
Number of subjects: 64
Study: 11975827

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 9727686

Group type: EXPERIMENTAL
Intervention: Conversion therapy (amiodarone for restoration and maintenance of sinus rhythm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of ventricular rate only (diltiazem as primary therapy)
Number of subjects: 0
Study: 8535958

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin ophthalmic ointment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin ophthalmic solution
Number of subjects: 13
Study: 2403734

Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (160 mg administered twice daily)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High-dose sotalol (320 mg administered twice daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 102
Study: 721790

Group type: EXPERIMENTAL
Intervention: Doxepin (112.7 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Imipramine (116.7 mg/day)
Number of subjects: 97
Study: 30561284

Group type: EXPERIMENTAL
Intervention: Novel handheld telehealth device (Tyto)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stand-alone digital examination devices (stethoscope and otoscope)
Number of subjects: 50
Study: 28193533

Group type: EXPERIMENTAL
Intervention: Dual-mode NIBS with high-frequency rTMS and tDCS
Number of subjects: 32

Group type: COMPARATOR
Intervention: rTMS alone with sham tDCS
Number of subjects: 32
Study: 26503099

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23704677

Group type: EXPERIMENTAL
Intervention: Youth with type 2 diabetes
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Age, diabetes duration, and mean HbA1c
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Highest BMI tertile
Number of subjects: 517
Study: 22208108

Group type: EXPERIMENTAL
Intervention: Being forgotten (Study 1)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Being forgotten (Study 2)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Being remembered (Study 2)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Being excluded (Study 2)
Number of subjects: 143
Study: 19278178

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.15 mg/kg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.3 mg/kg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 17216322

Group type: EXPERIMENTAL
Intervention: High spinal anesthesia (2.7 ml of 0.5% hyperbaric bupivacaine)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low spinal anesthesia (1.5 ml of 0.5% hyperbaric bupivacaine)
Number of subjects: 55
Study: 15577367

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bupivacaine (150 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg) and Bupivacaine (150 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study: 11378836

Group type: EXPERIMENTAL
Intervention: T102C 5-HT(2A) polymorphism in hypertensive subjects (female group)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 342
Study: 9235679

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (dextran‐70, low molecular weight heparin, and graded elastic stockings) during the first week after operation
Number of subjects: 258

Group type: COMPARATOR
Intervention: Clinical diagnostics by visiting doctors
Number of subjects: 258
Study: 7965237

Group type: EXPERIMENTAL
Intervention: Two 90‐minute interactive seminars
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual clerkship goals (Control)
Number of subjects: 146